Related Experiment Video
Updated: Jul 29, 2026
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay
J P Vaughn1, J D Iglehart, S Demirdji
1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
A causal role has been inferred for ERBB2 overexpression in the etiology of breast cancer and other epithelial malignancies. The development of therapeutics that inhibit this tyrosine kinase cell surface receptor remains a high priority. This report describes the specific downregulation of ERBB2 protein and mRNA in the breast cancer cell line SK-BR-3 by using antisense DNA phosphorothioates. An approach was developed to examine antisense effects which allows simultaneous measurements of antisense dose and gene specific regulation on a per cell basis. A fluorescein isothiocyanate end-labeled tracer oligonucleotide was codelivered with antisense DNA followed by immunofluorescent staining for ERBB2 protein expression. Two-color flow cytometry measured the amount of both intracellular oligonucleotide and ERBB2 protein. In addition, populations of cells that received various doses of nucleic acids were physically separated and studied. In any given transfection, a 100-fold variation in oligonucleotide dosage was found. ERBB2 protein expression was reduced greater than 50%, but only in cells within a relatively narrow uptake range. Steady-state ERBB2 mRNA levels were selectively diminished, indicating a specific antisense effect. Cells receiving the optimal antisense dose were sorted and analyzed for cell cycle changes. After 2 days of ERBB2 suppression, breast cancer cells showed an accumulation in the G1 phase of the cell cycle.
Insights
Antisense DNA phosphorothioates effectively reduced ERBB2 protein and mRNA in breast cancer cells. This targeted gene silencing led to G1 cell cycle arrest, offering a potential therapeutic strategy for ERBB2-positive malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- ERBB2 (ErbB-2) overexpression is implicated in breast cancer and other epithelial cancers.
- Targeting the ERBB2 tyrosine kinase receptor is a key therapeutic goal.
Purpose of the Study:
- To investigate the downregulation of ERBB2 protein and mRNA using antisense DNA phosphorothioates in SK-BR-3 breast cancer cells.
- To develop a method for measuring antisense effects on a per-cell basis, correlating dose with gene regulation.
Main Methods:
- Utilized antisense DNA phosphorothioates to target ERBB2.
- Employed a two-color flow cytometry approach with a fluorescently labeled tracer oligonucleotide to measure intracellular uptake and ERBB2 protein levels.
- Sorted cells based on nucleic acid uptake for detailed analysis.
Main Results:
- Achieved >50% reduction in ERBB2 protein expression within a specific oligonucleotide uptake range.
- Demonstrated selective diminution of steady-state ERBB2 mRNA levels, confirming specific antisense activity.
- Observed G1 phase cell cycle accumulation in breast cancer cells after 2 days of ERBB2 suppression.
Conclusions:
- Antisense DNA phosphorothioates can effectively downregulate ERBB2 expression in breast cancer cells.
- The developed method allows for precise assessment of antisense efficacy correlated with cellular uptake.
- ERBB2 suppression induces G1 cell cycle arrest, suggesting a potential therapeutic avenue for ERBB2-driven cancers.
